Structural and biophysical insight into cholesteryl ester-transfer protein

Biochemical Society Transactions

Volumn 39, Issue 4, 2011, Pages 1000-1005

  Hall, Justin ^a   Qiu, Xiayang ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cardiovascular disease (CVD); Cholesteryl ester transfer protein (CETP); Neutral lipid; Phospholipid; Triacylglycerol (TAG)

Indexed keywords

ANACETRAPIB; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPOLYSACCHARIDE BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; PHOSPHOLIPID TRANSFER PROTEIN; TORCETRAPIB; VERY LOW DENSITY LIPOPROTEIN;

ARTERIAL WALL THICKNESS; BINDING COMPETITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN STRUCTURE; SYSTOLIC BLOOD PRESSURE;

AMINO ACID SEQUENCE; ANIMALS; ANTICHOLESTEREMIC AGENTS; BINDING SITES; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CONSERVED SEQUENCE; EVOLUTION, MOLECULAR; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHOLIPIDS; PROTEIN CONFORMATION;

EID: 79960879255     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0391000     Document Type: Conference Paper

References (65)

1. Tall, A.R. (1990) Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J. Clin. Invest. 86, 379-384
2. Le Goff, W., Guerin, M. and Chapman, M.J. (2004) Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol. Ther. 101, 17-38
3. Barter, P.J., Brewer, Jr, H.B., Chapman, M.J., Hennekens, C.H., Rader, D.J. and Tall, A.R. (2003) Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 160-167
4. Schwartz, C.C., VandenBroek, J.M. and Cooper, P.S. (2004) Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid Res. 45, 1594-1607 (Pubitemid 39296198)
5. Brewer, Jr, H.B. (2004) High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 24, 387-391
6. Lamarche, B., Uffelman, K.D., Carpentier, A., Cohn, J.S., Steiner, G., Barrett, P.H. and Lewis, G.F. (1999) Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J. Clin. Invest. 103, 1191-1199
7. Chapman, M.J., Le Goff, W., Guerin, M. and Kontush, A. (2010) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 31, 149-164
8. Kappelle, P.J.W.H., van Tol, A., Wolffenbuttel, B.H.R. and Dullaart, R.P.F. (2010) Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Cardiovasc. Ther., doi:10.1111/j.1755-5922.2010.00201.x
9. Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B. and Dawber, T.R. (1977) High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am. J. Med. 62, 707-714
10. Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., Jacobs, Jr, D.R., Bangdiwala, S. and Tyroler, H.A. (1989) High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79, 8-15 (Pubitemid 19043669)
11. Assmann, G., Schulte, H, von Eckardstein, A. and Huang, Y. (1996) High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124, 11-20
12. Sharrett, A.R., Ballantyne, C.M., Coady, S.A., Heiss, G., Sorlie, P.D., Catellier, D. and Patsch, W. (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions. Circulation 104, 1108-1113 (Pubitemid 32830392)
13. Luc, G., Bard, J.M., Ferrières, J., Evans, A., Amouyel, P., Arveiler, D., Fruchart, J.C. and Ducimetière, P. (2002) Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective epidemiological study of myocardial infarctionArterioscler. Thromb. Vasc. Biol. 22, 1155-1161
14. Chapman, M.J. (2006) Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol. Ther. 111, 893-908
15. Nissen, S., Nicholls, S.J., Sipahi, I., Libby, P., Raichlen, J.S., Ballantyne, C.M., Davignon, J., Erbel, R., Fruchart, J.C., Tardif, J.C. et al. (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, J. Am. Med. Assoc. 295, 1556-1565
16. Taylor, A., Lee, H.J. and Sullenberger, L.E. (2006) The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. 22, 2243-2250
17. Nicholls, S., Tuzcu, E.M., Sipahi, I., Grasso, A.W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M.Y., Hazen, S.L. et al. (2007) Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA, J. Am. Med. Assoc. 297, 499-508
18. Brown, B. and Zhao, X.Q. (2008) Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am. J. Cardiol. 101, 58B-62B
19. Williams, K.J. and Tabas, I. (1995) The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15, 551-561
20. Reference deleted
21. Tall, A.R. (1993) Plasma cholesteryl ester transfer protein. J. Lipid Res. 34, 1255-1274
22. Koizumi, J., Mabuchi, H., Yoshimura, A., Michishita, I., Takeda, M., Itoh, H., Sakai, Y., Sakai, T., Ueda, K. and Takeda, R. (1985) Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 58, 175-186 (Pubitemid 16173307)
23. Inazu, A., Brown, M.L., Hesler, C.B., Agellon, L.B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H. and Tall, A.R. (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234-1238
24. Caslake, M.J., Stewart, G., Day, S.P., Daly, E., McTaggart, F., Chapman, M.J., Durrington, P., Laggner, P., Mackness, M., Pears, J. and Packard, C.J. (2003) Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 171, 245-253 (Pubitemid 37486076)
25. Schaefer, J.R., Schweer, H., Ikewaki, K., Stracke, H., Seyberth, H.J., Kaffarnik, H., Maisch, B. and Steinmetz, A. (1999) Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144, 177-184 (Pubitemid 29259979)
26. Guerin, M., Bruckert, E., Dolphin, P.J., Turpin, G. and Chapman, M.J. (1996) Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 16, 763-772
27. Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.C., Waters, D.D. et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122
28. Forrest, M.J., Bloomfield, D., Briscoe, R.J., Brown, P.N., Cumiskey, A.M., Ehrhart, J., Hershey, J.C., Keller, W.J., Ma, X., McPherson, H.E. et al. (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154, 1465-1473
29. Connelly, M.A., Parry, T.J., Giardino, E.C., Huang, Z., Cheung, W.M., Chen, C., Cools, F., Van der Linde, H., Gallacher, D.J., Kuo, G.H. et al. (2010) Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J. Cardiovasc. Pharmacol. 55, 459-468
30. Kastelein, J.J., van Leuven, S.I., Burgess, L., Evans, G.W., Kuivenhoven, J.A., Barter, P.J., Revkin, J.H., Grobbee, D.E., Riley, W.A., Shear, C.L. et al. (2007) Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620-1630
31. Bots, M.L., Visseren, F.L., Evans, G.W., Riley, W.A., Revkin, J.H., Tegeler, C.H., Shear, C.L., Duggan, W.T., Vicari, R.M., Grobbee, D.E. and Kastelein, J.J. (2007) Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370, 153-160 (Pubitemid 47042895)
32. Nissen, S.E., Tardif, J.C., Nicholls, S.J., Revkin, J.H., Shear, C.L., Duggan, W.T., Ruzyllo, W., Bachinsky, W.B., Lasala, G.P. and Tuzcu, E.M. (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316
33. Hu, X., Dietz, J.D., Xia, C., Knight, D.R., Loging, W.T., Smith, A.H., Yuan, H., Perry, D.A. and Keiser, J. (2009) Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 150, 2211-2219
34. Cannon, C.P., Shah, S., Dansky, H.M., Davidson, M., Brinton, E.A., Gotto, A.M., Stepanavage, M., Liu, S.X., Gibbons, P., Ashraf, T.B. et al. (2010) Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363, 2406-2415
35. Stevenson, S.C., Wang, S., Deng, L. and Tall, A.R. (1993) Human plasma cholesteryl ester transfer protein consists of a mixture of two forms reflecting variable glycosylation at asparagine 341. Biochemistry 32, 5121-5126 (Pubitemid 23162079)
36. Hesler, C.B., Brown, M.L., Feuer, D.S., Marcel, Y.L., Milne, R.W. and Tall, A.R. (1989) Structure-function analysis of plasma cholesteryl ester transfer protein by protease digestion and expression of cDNA fragments in Escherichia coli. J. Biol. Chem. 264, 11317-11325 (Pubitemid 19168866)
37. r 74,000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma. J. Biol. Chem. 263, 5020-5023
38. Swenson, T.L., Hesler, C.B., Brown, M.L., Quinet, E., Trotta, P.P., Haslanger, M.F., Gaeta, F.C., Marcel, Y.L., Milne, R.W. and Tall, A.R. (1989) Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope. J. Biol. Chem. 264, 14318-14326
39. Wang, S., Deng, L., Milne, R.W. and Tall, A.R. (1992) Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing monoclonal antibody and necessary for neutral lipid transfer activity. J. Biol. Chem. 267, 17487-17490
40. Fukasawa, M., Arai, H. and Inoue, K. (1992) Establishment of anti-human cholesteryl ester transfer protein monoclonal antibodies and radioimmunoassaying of the level of cholesteryl ester transfer protein in human plasma. J. Biochem. (Tokyo) 111, 696-698
41. Wang, S., Wang, X., Deng, L., Rassart, E., Milne, R. and Tall, A. (1993) Point mutagenesis of carboxyl-terminal amino acids of cholesteryl ester transfer protein: opposite faces of an amphipathic helix important for cholesteryl ester transfer or for binding neutralizing antibody. J. Biol. Chem. 268, 1955-1959
42. Ranalletta, M., Bierilo, K.K., Chen, Y., Milot, D., Chen, Q., Tung, E., Houde, C., Elowe, N.H., Garcia-Calvo, M., Porter, G. et al. (2010) Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51, 2739-2752
43. Clark, R.W., Ruggeri, R.B., Cunningham, D. and Bamberger, M.J. (2006) Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47, 537-552 (Pubitemid 43345595)
44. Cunningham, D., Lin, W., Hoth, L.R., Danley, D.E., Ruggeri, R.B., Geoghegan, K.F., Chrunyk, B.A. and Boyd, J.G. (2008) Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein. Bioconjugate Chem. 19, 1604-1613
45. Qiu, X., Mistry, A., Ammirati, M.J., Chrunyk, B.A., Clark, R.W., Cong, Y., Culp, J.S., Danley, D.E., Freeman, T.B., Geoghegan, K.F. et al. (2007) Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol. 14, 106-113
46. Cooley, R.B., Arp, D.J. and Karplus, P.A. (2010) Evolutionary origin of a secondary structure: π-helices as cryptic but widespread insertional variations of α-helices that enhance protein functionality. J. Mol. Biol. 404, 232-246
47. Bloom, J.D. and Arnold, F.H. (2009) In the light of directed evolution: pathways of adaptive protein evolution. Proc. Natl. Acad. Sci. U.S.A. 106 (Suppl. 1), 9995-10000
48. Hardy, J.A., Walsh, S.T. and Nelson, H.C. (2000) Role of an α-helical bulge in the yeast heat shock transcription factor. J. Mol. Biol. 295, 393-409
49. Worth, C.L., Gong, S. and Blundell, T.L. (2009) Structural and functional constraints in the evolution of protein families. Nat. Rev. 10, 709-720
50. Heinz, D.W., Baase, W.A., Dahlquist, F.W. and Matthews, B.W. (1993) How amino-acid insertions are allowed in an α-helix of T4 lysozyme. Nature 361, 561-564
51. Weaver, T.M. (2000) The π-helix translates structure into function. Protein Sci. 9, 201-206
52. Cartailler, J.P. and Luecke, H. (2004) Structural and functional characterization of π bulges and other short intrahelical deformations. Structure 12, 133-144
53. Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K. and Shinkai, H. (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203-207 (Pubitemid 30469005)
54. Beamer, L.J., Carroll, S.F. and Eisenberg, D. (1997) Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 276, 1861-1864
55. Kleiger, G., Beamer, L.J., Grothe, R., Mallick, P. and Eisenberg, D. (2000) The 1.7 angstrom crystal structure of BPI: a study of how two dissimilar amino acid sequences can adopt the same fold. J. Mol. Biol. 299, 1019-1034
56. Kolodziejczyk, R., Bujacz, G., Jakob, M., Ozyhar, A., Jaskolski, M. and Kochman, M. (2008) Insect juvenile hormone binding protein shows ancestral fold present in human lipid-binding proteins. J. Mol. Biol. 377, 870-881
57. Horwitz, A.H., Leigh, S.D., Abrahamson, S., Gazzano-Santoro, H., Liu, P.-S., Williams, R.E., Carroll, S.F. and Theofan, G. (1996) Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein. Protein Expression Purif. 8, 28-40 (Pubitemid 26326211)
58. 2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J. Biol. Chem. 262, 14891-14894
59. Ooi, C.E., Weiss, J., Doerfler, M.E. and Elsbach, P. (1991) Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability- increasing protein of human neutrophils. J. Exp. Med. 174, 649-655
60. Iovine, N., Eastvold, J., Elsbach, P., Weiss, J.P. and Gioannini, T.L. (2002) The carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein-lipopolysaccharide complexes. J. Biol. Chem. 277, 7970-7978
61. Barter, P.J. and Jones, M.E. (1980) Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins. J. Lipid Res. 21, 238-249 (Pubitemid 10115826)
62. Connolly, D.T., McIntyre, J., Heuvelman, D., Remsen, E.E., McKinnie, R.E., Vu, L., Melton, M., Monsell, R., Krul, E.S. and Glenn, K. (1996) Physical and kinetic characterization of recombinant human cholesteryl ester transfer protein. Biochem. J. 320, 39-47 (Pubitemid 26400158)
63. Ihm, J., Quinn, D.M., Busch, S.J., Chataing, B. and Harmony, J.A. (1982) Kinetics of plasma protein-catalyzed exchange of phosphatidylcholine and cholesteryl ester between plasma lipoproteins. J. Lipid Res. 23, 1328-1341 (Pubitemid 13165987)
64. Bailey, L.J., McCoy, J.G., Phillips, Jr, G.N. and Fox, B.G. (2008) Structural consequences of effector protein complex formation in a diiron hydroxylase. Proc. Natl Acad. Sci. U.S.A. 105, 19194-19198
65. Liu, S., Mistry, A., Reynolds, J.M., Lloyd, D.B., Griffor, M.C., Perry, D., Clark, R. W. and Qiu, X. (2010) Crystal structure of CETP in complex with inhibitors provides a new basis for drug design.